vs

Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and NOVO NORDISK A S (NVO). Click either name above to swap in a different company.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AARD
AARD
NVO
NVO
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Net Profit
AARD
AARD
NVO
NVO
Q4 25
$-17.6M
Q3 25
$-16.3M
Q2 25
$-14.4M
Q1 25
$-9.3M
EPS (diluted)
AARD
AARD
NVO
NVO
Q4 25
$-0.81
Q3 25
$-0.75
Q2 25
$-0.66
Q1 25
$-0.71

Related Comparisons